NYSEMKT: AEON
Aeon Biopharma Inc Stock Ownership - Who owns Aeon Biopharma?

Insider buying vs selling

Have Aeon Biopharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Timothy P. Lynch10% Owner2026-08-191,150,000$0.21
$243.80kBuy

1 of 1

AEON insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AEON insiders and whales buy or sell their stock.

AEON Shareholders

What type of owners hold Aeon Biopharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Daewoong Co Ltd28.89%14,409,737$3.70MInsider
Priveterra Sponsor LLC27.84%13,889,163$3.57MInsider
Timothy P. Lynch10.73%5,350,000$1.37MInsider
Robert E. Bancroft6.37%3,177,103$816.52kInsider
Robert J. Palmisano5.06%2,523,705$648.59kInsider
Chad Oh4.38%2,183,436$561.14kInsider
Alexander Blair Wilson4.38%2,183,005$561.03kInsider
Strathspey Crown Holdings Group LLC4.07%2,031,773$522.17kInsider
Jennifer Sy3.01%1,501,176$385.80kInsider
Marc Forth1.95%973,231$250.12kInsider

1 of 3

AEON vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AEON0.03%99.97%Net BuyingNet Buying
INTS0.04%3.92%Net BuyingNet Buying
PHIO0.00%100.00%Net SellingNet Selling
KPRX0.01%99.99%Net SellingNet Selling
ASBP0.00%100.00%

Aeon Biopharma Stock Ownership FAQ

Who owns Aeon Biopharma?

Aeon Biopharma (NYSEMKT: AEON) is owned by 0.03% institutional shareholders, 101.61% Aeon Biopharma insiders, and 0.00% retail investors. Daewoong Co Ltd is the largest individual Aeon Biopharma shareholder, owning 14.41M shares representing 28.89% of the company. Daewoong Co Ltd's Aeon Biopharma shares are currently valued at $3.54M.

If you're new to stock investing, here's how to buy Aeon Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.